A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Trial ID or NCT#
NCT05548296
Status
RECRUITING
Purpose
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.
Official Title
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
Investigator(s)
Ali Raza Khaki, MD
Genitourinary specialist,
Medical oncologist
Clinical Assistant Professor, Medicine - Oncology
Contact us to find out if this trial is right for you.
Contact
Denise Haas
650-736-1252
View on ClinicalTrials.gov
